HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hair dye/bladder cancer risk

This article was originally published in The Rose Sheet

Executive Summary

Permanent hair dye associated with bladder cancer in non-smoking women with genotype N-acetyltransferases 1, Manuela Gago-Dominguez, et al., University of Southern California, conclude in research presented during American Association of Cancer Research Annual meeting in San Francisco April 6-10. Case-control study was conducted in 450 female subjects in Los Angeles. In earlier research published in the International Journal of Cancer in 2001, Gago-Dominguez et al. determined women who use permanent hair dyes at least once a month increase their risk of contracting bladder cancer 2.1 times compared to non-users (1"The Rose Sheet" Feb. 5, 2001, p. 9). Cosmetic, Toiletry and Fragrance Association refuted the new research, stating that it is being "presented to scientists and the public for the first time and the complete report is yet to be presented and peer-reviewed...

You may also be interested in...



Hair Dye Literature Review Will Be Undertaken By CIR In September

The Cosmetic Ingredient Review Expert Panel will undertake a comprehensive literature review of hair dyes at its Sept. 8-9 meeting to evaluate the link between the use of hair dyes and incidence of cancer

Hair Dyes Increase Risk Of Bladder Cancer - USC Researchers

Women who use permanent hair dyes at least once a month increase their risk of contracting bladder cancer 2.1 times compared to non-users, according to a study conducted by Manuela Gago-Dominguez, et al., University of Southern California.

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010201

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel